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The cytochrome P450 (P450) superfamily
metabolizes many endogenous signaling mole-
cules and drugs. P450 enzymes are regulated
by posttranslational mechanisms in vivo, which
hinders their functional characterization by
conventional genomic or proteomic methods.
Here we describe a chemical proteomic strat-
egy to profile P450 activities directly in living
systems. Derivatization of a mechanism-based
inhibitor with a ‘‘clickable’’ handle provided
an activity-based probe that labels multiple
P450s both in proteomic extracts and in vivo.
This probe was used to record alterations in
liver P450 activities triggered by chemical
agents, including inducers of P450 expression
and direct P450 inhibitors. The chemical pro-
teomic strategy described herein thus offers
a versatile method to monitor P450 activities
and small-molecule interactions in any biologi-
cal system and, through doing so, should facil-
itate the functional characterization of this large
and diverse enzyme class.
INTRODUCTION
The mammalian cytochrome P450 (P450) membrane-
boundmonooxygenase enzyme familymetabolizes a large
number of xenobiotics, drugs, and endogenous signaling
molecules [1]. The human genome encodes 57 distinct
P450 enzymes [2], and, despite sharing a conserved
structural core with a reactive heme group at the active
site [3], these enzymes are remarkably diverse, exhibiting
as little as 16% sequence identity. Multiple P450 enzymes
participate in drug metabolism, and several demonstrate
broad substrate specificity [1]. Five human P450 enzymes
in particular contribute to the metabolism of 90% of
current clinical drugs, with P450 3A4 having a role in
more than 60% [2]. Other P450 enzymes are involved in
the biosynthesis and/or degradation of bioactive sterols,
fatty acids, and eicosanoids. Some of these enzymes,Chemistry & Biology 14, 1043–1051such as aromatase (P450 19A1), which is involved in the
biosynthesis of estrogen, have emerged as important
drug targets for the treatment of hormone-sensitive can-
cers [4]. Finally, a significant portion of the P450 family re-
mains essentially unannotated, with 20%–30% of human
P450s lacking known substrates [2].
The study of P450 drug metabolism has become a criti-
cal part of the pharmaceutical development process.
In vitro testing of P450 metabolism, inhibition, and induc-
tion is typically used to model P450-drug interactions
in vivo. Challenges in predicting from in vitro assays the
impact of drugs on P450 expression and/or activity in
vivo are well documented [5–12]. In vitro systems, such
as liver microsomes, hepatocyte cultures, and recombi-
nant P450 expression systems, do not account for the
variable distribution and uptake of drugs in living animals,
nor do they report accurately on the dynamic regulation
of P450 function in vivo. Indeed, the activity of P450
enzymes is regulated by multiple factors in vivo, including
membrane composition and localization, protein binding
partners (e.g., Dap1/PGRMC1) [13], posttranslational
modification [14–16], and endogenous concentrations of
cofactors (e.g., NADPH) and regulatory enzymes (e.g.,
NADPH-P450 reductases) [8]. The mechanisms of drug
interactions with P450 enzymes may also differ in vitro
and in vivo, as in the case of the H2 receptor antagonist
cimetidine, which acts as a reversible inhibitor in vitro but
appears to irreversibly inactivate P450s in vivo [17–20].
Due to the large size of the P450 family and the method-
ological complications associated with predicting its
activity and drug interactions using in vitro assays, there
has been great interest in developing methods to assess
P450 function in living systems. To date, these efforts
have largely been restricted to the coadministration of
drugs with P450 substrates, followed by evaluation of
excretedproducts to estimate drug effects onP450activity.
However, given the broad substrate selectivity of many
P450 enzymes, extrapolating the identity of specifically
affected P450 enzymes from indirect substrate assays
remains difficult [8–12]. Here we report an alternative
strategy that utilizes chemical probes to covalently label
P450 enzymes in an activity-based manner. Specifically,
we convert a broad-spectrum, mechanism-based P450
inhibitor, 2-ethynylnaphthalene (2EN), to an activity-based, September 2007 ª2007 Elsevier Ltd All rights reserved 1043
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Chemical Probes for Profiling Cytochrome P450sFigure 1. Reactivity of 2-Ethynylnaphthalene (2EN) Agents with Cytochrome P450 Enzymes
(A) Mechanism of inhibition of P450 enzymes by 2EN, where the aryl alkyne group of 2EN is first metabolized to an electrophilic ketene that then reacts
with amino acid residues in the P450 active site.
(B) Conversion of 2EN into an activity-based probe for P450 enzymes. Addition of an alkyl (unconjugated) acetylene group to 2EN provides a handle
for click chemistry conjugation to azide-modified rhodamine and/or biotin reporter groups (red ball).protein profiling (ABPP) probe by derivatization with a
versatile ‘‘click chemistry’’ (CC) handle that enables the
selective tagging, detection, enrichment, and identifica-
tion of P450 enzymes in any biological system. The 2EN
activity-based probe (2EN-ABP) was found to label sev-
eral P450 enzymes in rodent liver in an NADPH-dependent
manner, and proved capable of monitoring both drug
induction and inhibition of these enzymes in vivo.
RESULTS
Design and Synthesis of an Activity-Based Probe
for P450 Enzymes
Methods to characterize P450s in proteomes have been
intensely pursued; however, to date, these approaches
have been restricted tomeasurements of P450 expression
rather than activity [21]. An ideal functional proteomics
probe for the P450 superfamily would react with many
members of this enzyme class in a purely activity-based
manner. With this goal in mind, we selected the mecha-
nism-based inhibitor 2EN as the reactive group for a
P450-directed activity-based probe (Figure 1A). The inac-
tivation of P450 enzymes by aryl acetylenes, such as 2EN,
has been well characterized [22–25]. Briefly, the naphtha-
lene acts as a hydrophobic binding group to direct the
inhibitor toward P450 active sites, wherein enzyme-cata-
lyzed oxidation of the conjugated 2-acetylene generates
a highly reactive ketene (Figure 1A). The ketene intermedi-
ate can then acylate nucleophilic residues within the P450
active site or N-alkylate the bound heme molecule to gen-
erate covalent enzyme-inhibitor adducts. Although only
the former reaction product may be stable enough to fol-
low by ABPP methods, we anticipated that a certain level
of ‘‘nonproductive’’ heme alkylation could be tolerated, as
this process would only be expected to impact the sensi-
tivity (not fidelity) of probe-P450 reactions. Based on these1044 Chemistry & Biology 14, 1043–1051, September 2007 ª2mechanisms, we envisaged that a 2EN-derived probe
would exhibit high selectivity for labeling catalytically
active, but not inactive, P450 enzymes. 2EN has also been
shown to inhibit multiple subclasses of P450s, including
the 1, 2, and 3 families, and thus offered the potential for
broadproteomiccoverageof theP450superfamily [22–28].
Original strategies for ABPP employed chemical probes
that contained large reporter tags, such as biotin or fluoro-
phores, to permit the detection and enrichment of labeled
enzymes [29–31]; however, these bulky tags can, in cer-
tain cases, negatively impact probe-protein interactions
and hinder probe uptake and distribution in living systems.
As our goal was to create an activity-based probe that
could target P450 enzymes in vivo, we elected to modify
2EN with an alkyl (unconjugated) acetylene group (Fig-
ure 1B) to enable coupling of probe-modified enzymes
to reporter tags after the proteome labeling step via the
Cu(I)-catalyzed azide-alkyne [3 + 2] cycloaddition reac-
tion [click chemistry (CC)] [32–34]. The resulting agent
is referred to hereafter as 2EN-activity-based probe, or
2EN-ABP (Figure 1B).
Evidence that 2EN-ABP Labels P450s in an
Activity-Dependent Manner
The catalytic cycle of P450 enzymes requires the transfer
of two electrons from cytochrome P450 reductase [3].
These electrons are formally donated by NADPH; there-
fore, the catalytic activity of P450s is NADPH dependent.
To test whether 2EN-ABP labels P450s in an activity-
dependent manner, this probe was added to mouse liver
microsomes, a proteomic fraction that contains several
P450s, in the presence or absence of NADPH. Following
a 1 hr incubation, proteomes were treated with an azide-
conjugated rhodamine tag under CC conditions and
resolved by SDS-PAGE. In-gel fluorescence scanning
identified an intensely labeled set of protein bands in the007 Elsevier Ltd All rights reserved
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2EN-ABP
(A) Treatment of mouse liver microsomal
proteome (1 mg protein/ml) with 2EN-ABP
(10 mM) in the presence or absence of NADPH
(1 mM) resulted in selective NADPH-depen-
dent labeling of a set of 48–55 kDa proteins
(asterisk). Probe targets were detected by CC
with a rhodamine-azide tag, SDS-PAGE analy-
sis, and in-gel fluorescence scanning (fluores-
cent gel is shown in grayscale).
(B) Concentration dependence of 2EN-ABP
labeling of 48–55 kDa liver microsomal pro-
teins.
(C) Selective 2EN-ABP labeling of 48–55 kDa
proteins in liver microsomal proteomes com-
pared to cytosolic proteomes.
(D) Enhanced 2EN-ABP labeling of 48–55 kDa
proteins in liver microsomal proteomes
compared to other tissue microsomal pro-
teomes.
(E) Low levels of NADPH-dependent labeling for 48–55 kDa proteins were also observed at higher gel scanning intensity in small intestine.
(F) NADPH-dependent labeling by 2EN-ABP (10 mM) of human P450 1a2 recombinantly expressed in COS-7 cells. Probe labeling was blocked by
treatment with the P450 1a2 inhibitor a-naphthoflavone (aNF) (20 mM).molecular mass range of 48–55 kDa selectively in the
NADPH-treated proteome (Figure 2A). Labeling of these
proteins was dependent on the concentration of 2EN-
ABP,with signals saturating at approximately 20 mMprobe
(Figure 2B). The 48–55 kDa proteins were not detected in
soluble liver proteome (Figure 2C), nor were they observed
at high levels in other tissues, including kidney, lung, tes-
tis, heart, and brain (Figure 2D). NADPH-dependent label-
ing was observed in the small intestine upon increasing
the gel scan intensity (Figure 2E). The collective features
displayed by the 48–55 kDa targets of 2EN-ABP, including
NADPH-dependent labeling, molecular mass, and en-
hanced expression in liver microsomes (with lower levels
also observed in small intestine), suggested that they
could represent P450s from the 1, 2, and/or 3 families. To
test this premise directly, we next pursued the molecular
characterization of these proteins.
Liver microsomal proteome was treated with 2EN-ABP
in the presence or absence of NADPH for 1 hr, after which
the samples were reacted with a trifunctional azido-biotin-
rhodamine tag [33] under CC conditions. 2EN-ABP-
labeled proteins were enriched using streptavidin-conju-
gated beads, separated by SDS-PAGE, and detected by
in-gel fluorescence scanning. Strong fluorescent signals
were observed in the 48–55 kDa region of the gel in the
sample containing NADPH, but not in the sample lacking
NADPH (see Figure S1 in the Supplemental Data available
with this article online). This region of the gel was excised
for both samples, subjected to in-gel trypsin digestion,
and the resulting peptides analyzed by multidimensional
liquid chromatography-mass spectrometry (LC-MS) [35,
36]. Proteins were identified and quantified using the
SEQUEST search algorithm and spectral counting [36],
respectively. Five independent experiments were per-
formed, and specific targets of 2EN-ABP were identified
by filtering data for proteins that exhibited (1) at least five
spectral counts in each NADPH (+) sample; (2) at leastChemistry & Biology 14, 1043–1051a 3-fold increase in average spectral counts in NADPH
(+) versus NADPH (–) samples; and (3) a p value of
%0.01 for average spectral count differences in NADPH
(+) versus NADPH (–) samples.
Based on these criteria, several specific targets of 2EN-
ABP were identified, all of which represented members
of the P450 superfamily: 1a2, 3a11, 2c29, and 2d9/2d10
(Table 1). In the case of 2d9 and 2d10, a significant num-
ber of shared peptides were detected (Figure S2), which
precluded a confident decision on whether one or both
of these enzymes was targeted by 2EN-ABP. To confirm
that P450s were legitimate targets of 2EN-ABP, we
recombinantly expressed P450 1a2 in COS-7 cells. A
strongly labeled, NADPH-dependent target of 2EN-ABP
was detected in P450 1a2-transfected, but not mock-
transfected, COS-7 cells (Figure 2F).
Profiling P450 Induction and Drug Interactions
In Vitro with 2EN-ABP
Several drugs can induce, inhibit, or induce and inhibit
the expression and activity of P450 enzymes. For example,
b-naphthoflavone (bNF) and dexamethasone (DEX) are
known to induce the mouse P450 1a and 3a subfamilies,
respectively [37]. To test whether 2EN-ABP could detect
changes in P450 activity induced by drugs, we treated
mice with bNF (40mg/kg), DEX (80mg/kg), or vehicle daily
by intraperitoneal (i.p.) injection for 3 days, and, on the
fourth day, livers were harvested and microsomal pro-
teomes were prepared. Labeling of proteomes with 2EN-
ABP, followed by CC reaction with a rhodamine-azide tag,
SDS-PAGE, and in-gel fluorescence scanning, revealed a
striking elevation of multiple P450 activities in bNF-treated
mice (Figure 3A, arrowheads). In contrast, DEX treatment
did not significantly alter the 2EN-ABP labeling profiles as
judged by SDS-PAGE analysis (Figure 3A). These findings
were confirmed by quantification of results from six
independent experiments (Figure S3)., September 2007 ª2007 Elsevier Ltd All rights reserved 1045
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2EN-ABP in liver proteomes from bNF- and DEX-treated
mice and compared their activity signals to those
observed in untreated mice. bNF treatment induced a
dramatic increase in the activities of P450 1a1 and 1a2
(Figure 3B). The induction of P450 1a1 was particularly
striking, as this enzyme was virtually undetectable in livers
from untreated or DEX-treated mice (<5 spectral counts
per sample). A comparison of these LC-MS measure-
ments to the P450 activity signals observed by SDS-
PAGE permitted us to assign the bNF-induced 52 and
55 kDa targets as P450s 1a2 and 1a1, respectively
(Figure 3A). LC-MS analysis of 2EN-ABP targets in DEX-
treated mice revealed a selective elevation in the activity
of P450 3a11 compared to untreated or bNF-treated
mice (Figure 3B). We assume that the inability to detect
similar DEX-induced elevations in P450 3a11 activity by
SDS-PAGE was due to the presence of additional 2EN-
ABP-labeled P450s that comigrated with P450 3a11.
These results thus serve to underscore the enhanced
resolution afforded by LC-MS-based methods for ABPP,
which is especially relevant for enzyme classes such as
P450s that possess many members of similar molecular
mass. Interestingly, LC-MS data also revealed that P450
3a11 activity was significantly reduced in bNF-treated
mice compared to untreated animals (Figure 3B), indicat-
ing that the same drug can have opposing effects on the
activity of different members of the P450 family.
To test whether 2EN-ABP could also report on the direct
binding of drugs to P450 active sites, membrane pro-
teomes from P450 1a2-transfected COS-7 cells were
incubated with the reversible P450 1a2 inhibitor a-naph-
thoflavone (aNF; 20 mM) for 10 min prior to addition of
2EN-ABP (10 mM). aNF completely blocked labeling of
P450 1a2 by 2EN-ABP (Figure 2F). Equivalent results
Table 1. P450 Enzyme Activities Labeled by 2EN-ABP
in Mouse Liver Microsomes
Protein IPI Number
Tryptic Peptide Spectral Counts
In Vitro Labeling
In Vivo
Labeling
NADPH
(+)
NADPH
()
P450 1a2 IPI00128287 9 ± 1 0 ± 0 28 ± 6a
P450 3a11 IPI00134504 9 ± 1 0.6 ± 0.5 9 ± 2
P450 2c29 IPI00134503 13 ± 2 2 ± 1 21 ± 5
P450 2d9b IPI00116572 7 ± 1 1.4 ± 0.4 4 ± 2
P450 2d10b IPI00323908 10 ± 1 3.0 ± 1 7 ± 2
Data represent the average ± standard error of five indepen-
dent experiments.
IPI, International Protein Index.
a p = 0.02 for in vivo versus in vitro (NADPH [+]) labeled
samples (planned comparison).
b P450 2d9 and 2d10 shared approximately three to four
peptides in common per NADPH (+) sample, which precluded
confident assignment of whether one or both of these
enzymes was labeled by 2EN-ABP. See Figure S2 for a list
of peptides identified for each P450 enzyme.1046 Chemistry & Biology 14, 1043–1051, September 2007 ª2were obtained using liver microsomal proteomes from
bNF-induced mice, where 2EN-ABP labeling of endoge-
nous P450 1a2 was disrupted by treatment with aNF
(Figure 4A). An IC50 value of 2.0 ± 0.3 mM was calculated
for aNF inhibition of 2EN-ABP labeling of P450 1a2 in liver
proteomes (Figure 4B). Notably, this IC50 value matched
closely the IC50 value reported for aNF inhibition of mouse
P450 1a2 using standard substrate assays (0.8 mM) [38].
Collectively, these data demonstrate that 2EN-ABP can
accurately monitor changes in P450 activity in native pro-
teomes caused by either indirect induction or direct inhibi-
tion by drugs. We next considered whether 2EN-ABP
could provide similar data on P450 activities in vivo.
Profiling P450-Drug Interactions In Vivo
with 2EN-ABP
We next investigated whether 2EN-ABP could label P450
activities in vivo by administering this probe to adult male
mice over a dose range of 5–20 mg/kg (i.p.). Livers were
harvested 30 min after probe treatment and processed
for detection of labeled enzymes as described above.
Clear dose-dependent labeling of P450s was observed
Figure 3. Monitoring Drug Induction of P450 Activities with
2EN-ABP
(A) Liver proteomes frommice treated with b-naphthoflavone (bNF) (40
mg/kg, 3 days) showed augmented 2EN-ABP labeling of two 51–55
kDa (arrowheads) proteins compared to vehicle controls. Liver pro-
teomes from dexamethasone (DEX)-treated mice (80 mg/kg, 3 days)
did not show significant changes in 2EN-ABP labeling profiles com-
pared to vehicle- or bNF-treated mice as judged by SDS-PAGE.
(B) LC-MS analysis of 2EN-ABP-labeled enzymes from liver proteomes
of untreatedmice or mice treated with bNF and DEX. Data are reported
as average spectral counts (±standard error) for five independent
experiments per group. *p < 0.01 for bNF- or DEX-induced samples
relative to other groups. The signals for 2d9 and 2d10 are shown to-
gether because these enzymes shared too many peptides in common
to permit their individual assignment.007 Elsevier Ltd All rights reserved
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proteins were identified by LC-MS analysis as the major
P450 enzymes observed previously with in vitro prepara-
tions of mouse liver (Table 1). At the 20 mg/kg dose of
2EN-ABP, the signals for most P450s were on a par with
or greater than those observed in livermicrosomes treated
with 2EN-ABP in vitro (Table 1), indicating that in vivo
profiling of P450 activities can be accomplished without
a significant loss in sensitivity. The signals for P450 1a2,
in particular, were significantly higher for in vivo labeled
samples, perhaps indicating that this enzyme is more
active in the context of living animals.
Can in vivo profiling with 2EN-ABP detect changes in
the activity of P450s caused by drug treatment? To an-
swer this question, we first compared the in vivo labeling
profiles of mice treated with bNF or vehicle. A dramatic in-
crease in the in vivo labeling intensities of P450s 1a1 and
1a2 was observed in bNF-treated mice (Figure 5B), analo-
gous to the P450 activity patterns observed previously for
liver proteomes treated in vitro with 2EN-ABP (Figure 3A).
The significance of the bNF-induced changes in the in vivo
activities of P450 1a1 and 1a2 was confirmed by quantifi-
cation of six independent experiments (Figure S3). We
next tested whether 2EN-ABP could detect direct P450-
drug interactions in vivo by treating bNF-induced mice
with the P450 1a2 inhibitor aNF (80 mg/kg, i.p.) or vehicle
followed 30 min later by 2EN-ABP (20 mg/kg, i.p.). Mice
were sacrificed 30 min later and liver tissues were har-
Figure 4. Monitoring Inhibition of P450 Activities with
2EN-ABP
(A) Inhibition of 2EN-ABP labeling of P450 1a2 by aNF. Treatment of
liver microsomal proteome with increasing concentrations of aNF
(0–10 mM) resulted in concentration-dependent blockade of 2EN-ABP
labeling of the 52 kDa band designated as P450 1a2. Labeling condi-
tions: 2EN-ABP, 2.5 mM; proteome, 0.1 mg/ml; 6 min.
(B) IC50 curve for inhibition of 2EN labeling of P450 1a2 by aNF. The
calculated IC50 value of 2.0 ± 0.3 mM for aNF closely matched previous
literature values (0.8 mM) [40]. Data represent the average ± standard
error of four independent experiments per group.Chemistry & Biology 14, 1043–105vested and processed to detect P450 activities. A signifi-
cant reduction in the labeling intensity of P450 1a2 was
observed in mice treated with aNF (Figure 5C). A similar
reduction in P450 1a2 signals was observed by LC-MS
analysis of avidin-enriched samples from vehicle- versus
aNF-treated mice (Figure 5D). These results indicate that
2EN-ABP can be used to monitor the direct binding of
drugs to P450 active sites in living animals.
DISCUSSION
Activity-based protein profiling technologies have facili-
tated the functional proteomic analysis of several enzyme
classes [29–31]. The recent advent of tag-freemethods for
ABPP has provided avenues for profiling enzyme activities
directly in living systems [29, 31–33]. Building on these
precedents, we have reported herein an activity-based
probe for the cytochrome P450 superfamily of enzymes.
This agent, designated 2EN-ABP, satisfies all of the major
criteria expected for a bona fide functional proteomics
probe for the P450 enzyme class: (1) specific labeling of
active, but not inactive, P450s; (2) targeting of several
members of the P450 family; and (3) minimal crossreactiv-
ity with other proteins. Although it is unlikely that 2EN-ABP
will serve as a universal probe for all P450s due to differ-
ences in their substrate selectivity, the general principles
applied in this study, which exploit conserved features
of the P450 mechanism, should prove suitable for the
design of activity based probes for other members of this
enzyme class. Indeed, the creation of a library of structur-
ally diverse ‘‘clickable’’ P450 probes might prove particu-
larly useful for mapping the small molecule binding prefer-
ences of less well-characterized members of this enzyme
class. On this note, we should qualify that our original
probe, 2EN-ABP, could conceivably react with P450s at
either of its two alkyne groups (even though literature pre-
cedent would suggest preferred reactivity with the aryl
alkyne, at least with regard to P450 1a1 and 1a2 [25]). Re-
action at either site would still leave a free alkyne for sub-
sequent CC, which has been shown to be compatible with
either alkyl or aryl alkynes [39].
We have demonstrated a broad range of potential appli-
cations for 2EN-ABP. First, this probe can be used to
inventory P450 activities in any biological sample, includ-
ing cells, tissues, and living animals. We anticipate that
2EN-ABP will prove of value for comparatively profiling
P450 activities in diseases such as cancer, where these
enzymes play important roles in the metabolism of signal-
ing hormones and chemotherapeutic agents [40–42]. We
have also shown that key aspects of P450-drug interac-
tions, including enzyme induction and inhibition, can be
discerned with 2EN-ABP both in vitro and in vivo. Notably,
2EN-ABP was able to detect the inhibition of P450 1a2 in
mice by aNF, an inhibitor of only moderate potency with
mouse P450 1a2 (IC50 value of 2.0 mM). These data
indicate that even relatively modest-affinity P450-drug
interactions can be detected in vivo using 2EN-ABP.
The ability to monitor drug effects on P450 activities in
living systems, where the various dynamic processes1, September 2007 ª2007 Elsevier Ltd All rights reserved 1047
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with 2EN-ABP
(A) Labeling of P450 enzymes by 2EN-ABP in
mice. Mice were treated with the indicated
doses of 2EN-ABP for 30 min and then sacri-
ficed and their liver proteomes analyzed for
P450 labeling using CC methods. Dose-
dependent labeling was observed of P450
enzymes by 2EN-ABP.
(B) Following treatment with bNF (40 mg/kg;
i.p., once-per-day dosing for 3 days), mice
were administered 2EN-ABP (20 mg/kg, i.p.)
and, after 30 min, sacrificed and their liver pro-
teomes analyzed for P450 labeling. Elevated
labeling of protein bands corresponding to
P450s 1a1 and 1a2 was observed in bNF-
treated mice.
(C and D) Blockade of 2EN-ABP labeling of
P450 1a2 in vivo by pretreatment with aNF
(80 mg/kg), as judged by in-gel fluorescence
scanning (C) or LC-MS analysis and spectral
counting (D). Mice pretreated with bNF were
used in this study to augment P450 1a2 sig-
nals. *p < 0.01 for aNF-treated versus vehicle
controls (planned comparison). Data represent
the average ± standard error of four indepen-
dent experiments per group.that regulate P450 function are maintained, may help re-
searchers make informed decisions about the suitability
of drug candidates at early preclinical stages of develop-
ment. Historically, the pharmaceutical industry has relied
on in vitro data and modeling to predict drug interactions
with P450s in vivo [7–11]. Though many time-tested phar-
maceuticals have been developed using this standard
approach, complications from drug-drug interactions
still present a serious risk that results in hospitalization
for millions worldwide per year [3, 43]. This problem is
likely to escalate in the future as our population ages
and polytherapy becomes more common. P450 subfam-
ilies 1, 2, and 3 play important roles in both human and
mouse xenobiotic metabolism [2]. Our data indicate that
2EN-ABP targets several key members of these P450
subfamilies. Human P450 1a2 is inducible by cigarette
smoking and oxidizes procarcinogens, and is suggested
to participate in the metabolism of approximately 10%–
15% of marketed drugs [44, 45]. P450 3a11 is considered
to be the mouse congenator of human P450 3A4, which
is involved in the metabolism of greater than 60% of
marketed drugs [45]. P450 2d9 is a male-specific enzyme
in mice that may be related to human 2d6, an important
P450 for drug metabolism, including the therapeutics
minaprine and indinivar [46]. These findings collectively
indicate that 2EN-ABP is primed to report on P450-drug
interactions of relevance to the development of a wide
range of pharmaceuticals.
One limitation of our chemical proteomic approach for
in vivo profiling of P450 activities is that its application is
restricted to cell and animal model systems. Although
rodents are routinely used as in vivomodels for P450 func-
tional analysis and drug metabolism studies, their P4501048 Chemistry & Biology 14, 1043–1051, September 2007 ªrepertoires are quite distinct from that of humans (e.g.,
mice contain 102 putatively functional P450 enzymes
compared to only 57 for humans) [47, 48]. These differ-
ences create complications in making direct comparisons
between the function of P450s in rodents and humans.
Nonetheless, significant research efforts have been
devoted to determining functional orthologs for rodent and
human P450s, and it does appear that correlations can be
drawn between the 1a, 2d, and 3a subfamilies across
these species. In contrast, other subfamilies, such as 2c,
are more challenging to interpret [47, 48]. To overcome
this drawback, additional animal models, such as rabbits,
dogs, and primates, that are known to possess closer
correlates of human P450s could be used for in vivo ABPP
experiments [47]. The continued creation of transgenic
mouse models that express human P450 enzymes should
also prove useful [49–52].
In summary, we envision that P450-directed ABPP
probes will serve as valuable research tools for the func-
tional characterization of this large and diverse enzyme
family. In addition to their application for the proteomic
profiling of P450 activities and small-molecule interac-
tions, the compatibility of these probes with living systems
opens up future possibilities for their incorporation into
cell-based screens [53] to assess the functional con-
tribution of P450 enzymes in a wide range of biological
processes.
SIGNIFICANCE
Cytochrome P450 enzymes represent a large and
diverse protein family in mammals which play key
roles in the metabolism of endogenous signaling2007 Elsevier Ltd All rights reserved
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standing of P450 biology has increased, it has become
apparent that these enzymes can be regulated by
a number of posttranslational events in vivo, including
availability of catalytic cofactors, posttranslational
modifications, and protein-protein interactions. These
layers of biological complexity emphasize the need for
advanced proteomic tools to monitor the functional
state of P450s in native biological systems. Herein we
have described the design, synthesis, and character-
ization of a class of chemical proteomic probes for
profiling P450 activities. A broad-spectrum, mecha-
nism-based P450 inhibitor, 2-ethynylnaphthalene, was
converted into an activity-based probe by derivati-
zation with a versatile click chemistry handle that
enables the selective tagging, detection, enrichment,
and identification of P450 enzymes in any biological
system. The probewas found to label several P450 en-
zymes in rodent liver in anNADPH-dependentmanner,
and proved capable of monitoring both drug induction
and inhibition of these enzymes in vivo. We anticipate
that chemical proteomic probes will serve as valuable
research tools for the functional characterization of
P450 activities and small-molecule interactions in a
wide range of biological systems.
EXPERIMENTAL PROCEDURES
Synthesis of 2EN-ABP
See the Supplemental Data.
Preparation of Mouse Tissue Proteomes
Livers were harvested from male C57Bl/6J mice and processed
according to prior methods with some minor changes [54]. Mice
were anesthetized with a CO2/O2 mixture, and euthanized with CO2.
Livers were harvested, rinsed with ice-cold 1.5% KCl, finely diced
with a razor blade, and dounce homogenized in 250 mM sucrose
(5 ml per liver) in PBS buffer. EDTA was not included in the buffer
due to incompatibility with subsequent CC reactions. Liver homoge-
nates were then treated with a tissue tearor for five pulses. High-speed
centrifugation was used to remove the heavy membrane components
and ultimately isolate microsomes: 10,000 3 g (25 min, pellet = heavy
membrane fraction) to obtain the S9 fraction, 100,000 3 g (90 min,
pellet = microsome fraction). Microsomes were resuspended in 250
mM sucrose in PBS buffer with minimal dounce homogenization. All
samples were stored at 80C until use. Samples were subjected to
no more than two freeze-thaw cycles.
Recombinant Expression of P450 Enzymes in COS-7 Cells
COS-7 cells were grown to 80% confluency, and transfections were
carried out with a human P450 1a2 cDNA (Open Biosystems) accord-
ing to previously described methods [55]. Transfected cells were then
harvested, sonicated, dounce homogenized in PBS buffer, and
centrifuged at 100,000 3 g (60 min, pellet = membrane fraction). The
membrane fraction was resuspended in PBS buffer with minimal
sonication.
In Vitro Labeling of P450 Enzymes in Cell and Tissue
Proteomes with 2EN-ABP
Proteomes (50 ml of 1.0 mg/ml protein in PBS) were treated with 2EN-
ABP (10 mMunless otherwise noted, 0.5 ml of a stock solution in DMSO)
in the presence or absence of NADPH (1 mM final concentration, 0.5 ml
of a stock solution in PBS). Samples were incubated at 37C for 45min.
For drug induction studies, male C57Bl/6J mice were treated withChemistry & Biology 14, 1043–1051dexamethasone or b-naphthoflavone (bNF) (80 or 40 mg/kg, i.p.,
respectively) in vehicle (18:1:1 saline:emulphor:ethanol) once daily
for 3 days. On the fourth day, livers were collected and analyzed as
described above.
Following incubation with 2EN-ABP, proteomes were treated with
an azide-rhodamine reporter group (0.5 ml of a 6 mM stock solution
in DMSO) followed by 1 mM tris(2-carboxyethyl) phosphine (TCEP)
(253 stock in water) and 100 mM ligand (173 stock in DMSO:t-butanol,
1:4). The samples were vortexed and then 1 mM CuSO4 (503 stock in
water) was added. Samples were vortexed again and left at room
temperature in the dark for 1 hr, at which time 23 SDS-PAGE loading
buffer (reducing) was added to each reaction. The samples were
heated at 90C for 8 min and then loaded onto gels (30 ml per well).
Inhibition of 2EN-ABP Labeling of P450 1a2 by aNF
Liver microsomal proteomes (50 ml of 0.1 mg/ml protein in PBS) from
bNF-induced mice were treated with aNF (0–10 mM, 0.5 ml of a stock
solution in DMSO for each concentration), and NADPH was added to
the samples (0.5 mM final concentration, 0.5 ml of a stock solution in
PBS). Samples were incubated at 37C for 10 min, after which 2EN-
ABP was added (2.5 mM, 0.5 ml of a stock solution in DMSO), and
incubations proceeded at 37C for an additional 6min prior to analysis.
In Vivo Labeling of P450 Enzymes in Mice with 2EN-ABP
Male C57Bl/6J mice were administered 2EN-ABP (20 mg/kg, i.p., un-
less otherwise noted) in a vehicle of 18:1:1 saline:emulphor:ethanol at
a volume of 10 ml/g weight. Control mice were injected with vehicle
alone (listed as 0 mg/kg). After 30 min, the mice were anesthetized
with a CO2/O2mixture and euthanized with CO2. Livers were harvested
as described above. For inhibition studies, aNF (80mg/kg in the above
vehicle) was administered by i.p. injection to bNF-induced mice on the
fourth day. After 30 min, mice were administered 2EN-ABP. Following
an additional 30 min, the mice were euthanized and liver tissue was
harvested and analyzed as described above.
Supplemental Data
Supplemental Data include three figures and Supplemental Experi-
mental Procedures and are available at http://www.chembiol.com/
cgi/content/full/14/9/1043/DC1/.
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